Free Trial
NASDAQ:INCY

Incyte (INCY) Stock Price, News & Analysis

Incyte logo
$68.10 -0.27 (-0.39%)
As of 06/30/2025 04:00 PM Eastern

About Incyte Stock (NASDAQ:INCY)

Key Stats

Today's Range
$67.67
$68.82
50-Day Range
$57.38
$71.22
52-Week Range
$53.56
$83.95
Volume
1.48 million shs
Average Volume
1.98 million shs
Market Capitalization
$13.18 billion
P/E Ratio
212.82
Dividend Yield
N/A
Price Target
$74.53
Consensus Rating
Hold

Company Overview

Incyte Corporation, founded in 2002 and headquartered in Wilmington, Delaware, is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies in oncology and inflammation. The company has established a reputation for its targeted approach to drug development, focusing on molecular pathways that regulate cellular growth and immune responses. Incyte’s research-driven model seeks to address unmet medical needs by advancing compounds through preclinical studies into late-stage clinical trials and regulatory approval.

The company’s flagship product, Jakafi (ruxolitinib), was the first selective inhibitor of the Janus kinase (JAK) pathway to gain approval in the United States and Europe. Jakafi is indicated for the treatment of myelofibrosis and polycythemia vera, and has become a cornerstone therapy in these rare blood disorders. Beyond Jakafi, Incyte’s portfolio includes additional oncology and inflammatory candidates, encompassing small molecules and biologics that target epigenetic modifiers, immune checkpoints and growth factor receptors.

Incyte maintains a global presence, with commercial operations in North America, Europe and Asia. The company collaborates with major pharmaceutical partners to broaden access to its therapies, leveraging strategic alliances for regulatory filings, manufacturing and marketing. Incyte’s clinical pipeline spans multiple tumor types and autoimmune conditions, underscoring its commitment to advancing precision medicine across diverse patient populations.

Under the leadership of President and Chief Executive Officer Hervé Hoppenot, Incyte continues to invest in early-stage research and external innovation through collaborations and licensing agreements. The executive team, composed of experienced drug developers and industry veterans, guides Incyte’s efforts to expand its pipeline, pursue regulatory milestones and ultimately deliver new treatment options for patients worldwide.

AI Generated. May Contain Errors.

Incyte Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
87th Percentile Overall Score

INCY MarketRank™: 

Incyte scored higher than 87% of companies evaluated by MarketBeat, and ranked 139th out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Incyte has received a consensus rating of Hold. The company's average rating score is 2.22, and is based on 5 buy ratings, 12 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Incyte has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Incyte's stock forecast and price target.
  • Earnings Growth

    Earnings for Incyte are expected to grow by 34.57% in the coming year, from $4.86 to $6.54 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Incyte is 212.82, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.88.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Incyte is 212.82, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.34.

  • Price to Earnings Growth Ratio

    Incyte has a PEG Ratio of 0.58. PEG Ratios below 1 indicate that a company could be undervalued.

  • Price to Book Value per Share Ratio

    Incyte has a P/B Ratio of 3.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Incyte's valuation and earnings.
  • Percentage of Shares Shorted

    4.29% of the float of Incyte has been sold short.
  • Short Interest Ratio / Days to Cover

    Incyte has a short interest ratio ("days to cover") of 4.1.
  • Change versus previous month

    Short interest in Incyte has recently decreased by 2.85%, indicating that investor sentiment is improving.
  • Dividend Yield

    Incyte does not currently pay a dividend.

  • Dividend Growth

    Incyte does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.29% of the float of Incyte has been sold short.
  • Short Interest Ratio / Days to Cover

    Incyte has a short interest ratio ("days to cover") of 4.1.
  • Change versus previous month

    Short interest in Incyte has recently decreased by 2.85%, indicating that investor sentiment is improving.
  • News Sentiment

    Incyte has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 26 news articles for Incyte this week, compared to 17 articles on an average week.
  • Search Interest

    10 people have searched for INCY on MarketBeat in the last 30 days. This is an increase of 233% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Incyte to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Incyte insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    17.80% of the stock of Incyte is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    96.97% of the stock of Incyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Incyte's insider trading history.
Receive INCY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Incyte and its competitors with MarketBeat's FREE daily newsletter.

INCY Stock News Headlines

A grave, grave error.
Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the key to unlocking technological breakthroughs we once thought were impossible. And it may just be the only thing capable of bringing America back from the brink of recession – despite Washington’s incompetence and addiction to reckless spending. That’s why Elon Musk, Jeff Bezos, Jensen Huang, and even Bill Gates are pouring billions into the infrastructure behind it.
See More Headlines

INCY Stock Analysis - Frequently Asked Questions

Incyte's stock was trading at $69.07 at the start of the year. Since then, INCY shares have decreased by 1.4% and is now trading at $68.10.
View the best growth stocks for 2025 here
.

Incyte Corporation (NASDAQ:INCY) announced its quarterly earnings results on Tuesday, April, 29th. The biopharmaceutical company reported $1.16 earnings per share for the quarter, topping analysts' consensus estimates of $1.01 by $0.15. The business's revenue was up 19.5% on a year-over-year basis.
Read the conference call transcript
.

Shares of INCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Incyte investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), TotalEnergies (TTE) and Southern First Bancshares (SFST).

Company Calendar

Last Earnings
4/29/2025
Today
6/30/2025
Next Earnings (Estimated)
7/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:INCY
Employees
2,617
Year Founded
1991

Price Target and Rating

Average Stock Price Target
$74.53
High Stock Price Target
$107.00
Low Stock Price Target
$52.00
Potential Upside/Downside
+9.4%
Consensus Rating
Hold
Rating Score (0-4)
2.22
Research Coverage
18 Analysts

Profitability

Trailing P/E Ratio
212.82
Forward P/E Ratio
14.01
P/E Growth
0.58
Net Income
$32.62 million
Pretax Margin
7.13%

Debt

Sales & Book Value

Annual Sales
$4.24 billion
Cash Flow
$0.55 per share
Price / Cash Flow
123.50
Book Value
$17.90 per share
Price / Book
3.80

Miscellaneous

Free Float
159,115,000
Market Cap
$13.18 billion
Optionable
Optionable
Beta
0.67

Social Links

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:INCY) was last updated on 7/1/2025 by MarketBeat.com Staff
From Our Partners